In this study we followed up the side effects of adjuvant radiotherapy in patients with testicular seminoma stage I over a period from 13 to 84 months (median 28 months). The most frequent side effects during radiotherapy were gastrointestinal (nausea/vomiting), psychological, cognitive, and minor sexual problems. The reported side effects were treated by antiemetics and anxiolytics. After radiotherapy, the side effects persisted in 6 % of patients, but only a few of them required additional treatment. Healthy children were born to 76 % of patients in the 18 to 39 years age group. This study shows that adjuvant radiotherapy of the para-aortic lymph nodes with the total dosage of 24 Gy in 16 daily fractions administered to testicular seminoma patients causes acceptable side effects, does not adversely affect quality of life and fertility, if the approach to treatment is individual and family consulting is provided. This makes adjuvant radiotherapy of the para-aortic lymph nodes an acceptable treatment for testicular seminoma stage I patients. Testicular germ cell tumours are relatively rare, appearing in 1 % of all tumours in male patients (1). Most of these tumours originate in germ cells (seminoma and non-seminoma germ cell testicular tumours, sometimes the combination of these two groups), and more than 70 % of patients are diagnosed the disease while it is still in stage I. These malignancies represent the most common solid tumours in young men aged 25 to 35 years and are highly curable.
Testicular germ cell tumours are relatively rare, appearing in 1 % of all tumours in male patients (1) . Most of these tumours originate in germ cells (seminoma and non-seminoma germ cell testicular tumours, sometimes the combination of these two groups), and more than 70 % of patients are diagnosed the disease while it is still in stage I. These malignancies represent the most common solid tumours in young men aged 25 to 35 years and are highly curable.
Pure seminoma is the most common variant of testicular germ cell tumours, accounting for in about 40 % of all cases. Seminoma is highly radiosensitive and chemosensitive (2) . Adjuvant radiotherapy of the para-aortic lymph nodes after orchidectomy is one of the three approaches to management, which include surveillance, adjuvant radiotherapy (infradiaphragmatic 20 Gy to 25 Gy to include the para-aortic nodes), and adjuvant chemotherapy with carboplatin with area under the curve =7, (AUC=7) x 1 cycle or AUC=7 x 2 cycles (3) (4) (5) (6) .
Many surveillance studies suggest that 15 % to 20 % of these patients develop a metastatic disease. The adjuvant therapy is successful in 96 % to 100 % of patients (4, 7, 8) . Many studies suggest that carboplatin is not inferior to adjuvant radiotherapy in preventing metastatic relapse. The estimation of the therapy success, however, should include the quality of life during as well as after therapy. To improve the quality of life , it is therefore advisable to know which side effects to expect and how to prevent them).
The aim of this study was to establish the side effects during and after radiotherapy in patients with testicular seminoma stage I and how to prevention and/or treat them.
References provide numerous data on toxicity of radiotherapy in the adjuvant treatment of testicular seminoma. Most of the clinical studies of long-term surveillance are based on larger irradiation fi elds or higher daily doses. There are neither suffi cient data on the long-term surveillance of patients treated with irradiation of the para-aortic fi elds, nor on the adjuvant chemotherapy with carboplatin. The usual toxicity after radiotherapy and chemotherapy is either the acute toxicity during and immediately after therapy, or the late or postponed toxicity monitored years after the therapy.
Acute toxicity usually involves mild gastrointestinal symptoms and the symptoms of myelosuppression, but late effects may include radiation-induced secondary malignancies, increased risk of peptic ulceration, and impaired fertility, and sexual function (9-11).
SUBJECTS AND METHODS
The study included 115 patients with testicular seminoma stage I, treated with adjuvant radiotherapy at the Clinical Hospital Centre Zagreb, Department of Oncology. The average patient age at diagnosis was 34 (19 to 72) years. Their socio-demographic characteristics are summarised in Table 1 . All patients were treated with adjuvant radiotherapy of the paraaortic lymph nodes with 15 MV linear accelerator photons from two opposite anteroposterior fi elds. The tumour dose was 24 Gy divided in 16 daily fractions. Para-aortic fi eld borders included superior T10/T11 intervertebral disk, inferior L5/S1 intervertebral disk, lateral margins to the vertebral bodies including the transverse process bilaterally (Figure 1a,1b,1c) , and the left renal hilum for the left testicular seminoma. The patients wore a gonadal shield. All patients were stage IA or IB. Before orchidectomy, all had standard laboratory tests, tests for serum tumour markers alphafetoprotein (AFP), lactate dehydrogenase (LDH), and beta-human chorionic gonadotropin (bHCG), chest X-rays, abdominopelvic CT scans, and the ultrasound of the testes.
Before radiotherapy (post-orchidectomy), all patients had normal serum tumour markers LDH, bHCG, and AFP. Before orchidectomy 18 % had abnormal bHCG and 14 % abnormal LDH. Follow-up after radiotherapy took place every six months in the fi rst fi ve years, then annualy and included standard laboratory tests, AFP, LDH, and bHCG tests; chest X-rays, abdominopelvic CT scans or MRI, and the ultrasound of the testes.
For the follow-up of radiotherapy side effects we used the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire (12, 13) and the recommended toxicity criteria of the Radiation Therapy Oncology Group (RTOG) (14) . In the questionnaire the patients evaluated the severity of their side effects on a four-point scale: 1) not at all; 2) a little; 3) quite a bit; 4) very much (12) . Their physical condition and the quality of life were scored on a seven-point scale from "very poor" to "excellent". A smaller part of the data was taken from standard routine medical checkup documentation. Patients filled out the questionnaire immediately after radiotherapy and again in December of 2010, which means that the fi rst and the second questionnaire were separated by 13 to 84 months (median 28 months).
RESULTS AND DISCUSSION
The male population with testicular seminoma is generally of younger age. Due to successful therapy management, long-term survival is excellent. Therefore, seminoma patients are an ideal population to formulate evidence-based guidelines for reducing therapy side effects.
During and after radiotherapy, our patients complained of gastrointestinal side effects, fatigue and diminished fitness, affected psychological and cognitive functions and sexual problems. The sexual side effects are given in Figure 2 . Other side effects listed in Table 2 One patient had to withdraw from radiotherapy for three days due to thrombocytopenia G1, according to RTOG (14) .
After radiotherapy, six patients showed side effects; three required no therapy, while three required therapy occasionally. Occasional side effects were gastritis or stomach pain, which were treated with esomeprazol magnesium 20 mg d -1 . One patient had occasional diarrhoea for up to three months after radiotherapy, but required no therapy. A year after radiotherapy, one patient had two episodes of acute pancreatitis, which required hospitalisation. One to six years after radiotherapy, 80 % of the patients aged from 18 to 29 years and 67 % of those aged 30 to 39 years had healthy children.
Two patients had a relapse of seminoma (1.7 %). The fi rst was irradiated in 2008. He had a left testicular seminoma pT2, a lymphatic invasion and extending through the tunica albuginea, pT2N0M0S0, stage IB. The pathohistological tumour size was 4.5 cm. Fourteen months after the para-aortic radiotherapy, CT detected the lymph node size 5.5 cm x 5.6 cm (outside of the irradiation fi eld) in the left pelvis. He was treated with four cycles of BEP chemotherapy and is now healthy. The second patient had a relapse of seminoma in the right inguinal lymphnodes four months after the para-aortic radiotherapy. Initially, he had a right testicular seminoma pT2N0M0S0, stage IB. The pathohistological tumour size was 7.3 cm with a vascular invasion. He was treated with three cycles of BEP chemotherapy and is now healthy.
Seminomas are highly sensitive to chemotherapy and radiotherapy. Two management approaches have dominated the clinical practice in the past 20 years: irradiation and survival follow up. Currently, monochemotherapy with carboplatin may be proposed as the third approach. The role of adjuvant monochemotherapy with carboplatin is less established (15) (16) (17) .
Two Medical Research Council (MRC) studies of 5 years follow-up (18, 19) reported signifi cantly lower toxic effects after the radiotherapy of testicular seminoma when the fi eld was reduced from "dogleg" to para-aortic and when the dose was reduced from 30 Gy to 20 Gy, while the therapy outcome was the same.
A meta-analysis (20) of surveillance studies suggest that risk factors such as the tumour size >4 cm and the pathological infi ltration of rete testis result in 15 % to 20 % of testicular seminoma in patients with undetectable disease in the para-aortic region. Therefore, follow-up should include patients with no risk factors (7, 21) . The problem with follow up is the number of patients who come to the control examination irregularly. Beside the side effects, the quality of life is also important parameter included in follow-up.
Opinions are divided on the choice of treatment with carboplatin between one and two cycles and the respective dosage. However, the relapse is less likely with carboplatin in two cycles (AUC 7) (22-25). As for chemotherapy and radiotherapy, present data (4) suggests that the effects of treating testicular seminoma stage I with carboplatin or with irradiation of the paraaortic lymph nodes are identical. This shifts the focus on the side effects as important elements in the correct selection of treatment, in which patient's agreement is part of the decision process (26) .
Dose reduction and the limiting of the irradiation field to the para-aortic area seem to reduce the scattered dosage to the remaining testicle, and therefore the risk of impaired fertility and genetic damage. Additionally, the cumulative dose of 2 Gy in multiple fractions was reported to induce azoospermia, which may be associated with scattered irradiation of the testis from inverted Y fi eld (27, 28) .
Chemotherapy of Hodgkin's disease alone caused less severe fertility function disturbances than a combination of chemotherapy and pelvic irradiation (48 % vs. 89 %) (29) .
Advances in radiotherapy and chemotherapy with similar results may in near future provide an answer as to which therapy option is less toxic (30). Radiotherapy has been the accepted cancer therapy option for at least fi ve decades. Our study describes side effects in patients with testicular seminoma stage I after radiotherapy and is in concordance with similar studies (11, 31) . According to a large multicentre studies, 4 % to 7 % of patients developed the secondary cancer after radiotherapy of testicular cancer, of which the highest risk was for gastrointestinal cancers (9, 32) . In the past, however, irradiation fi elds were larger and so was the total dose of irradiation (33, 34) . A transparent communication and individual approach to patients will produce the best results and better treatment of radiotherapy side effects. The important problem is the change in sexual activity due to either psychological reasons (35, 36) or the awareness of fertility issues (11, 28) . This study contributes to the current knowledge of patient condition after exposure to ionising radiation, fertility options, side effects in order to identify procedures for resolving patient's problems and improving living conditions as soon after radiotherapy as possible.
